Erbitux slows cancer growth by targeting a protein found on the surface of some cells called the epidermal growth factor receptor (EGFR). EGFR plays a role in cell growth and is present in about 75% of colon cancers.
FDA Approved
2004
Common Side Effects
- Loss of appetite, nausea and/or vomiting
- Fatigue
- Dry skin, acne and/or rashes
- Itching
- Body aches
